# Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches

> **Open Intelligence Dossier** · First detected: 2026-09-28 19:20 UTC · Category: Business

## Executive Summary
Adicet Bio's experimental CAR-T therapy sparks early lupus remissions, drawing widespread industry attention.

## Intelligence Brief
Recent coverage highlights significant developments surrounding Adicet Bio and its investigational treatment, prula-cel, formerly known as ADI-001. According to reports from multiple outlets, the company announced positive safety and efficacy data from a clinical study evaluating the therapy in patients suffering from systemic lupus erythematosus, both with and without lupus nephritis. The data specifically point toward encouraging signs of lupus remissions, which reporting describes as a potential new era for addressing autoimmune treatment approaches. Financial markets and media platforms quickly responded to the data release. Outlets including Investing.com India noted that Wedbush raised its stock price target for Adicet Bio following the trial disclosures.


Stock Titan coverage previously indicated that data concerning this potential lupus treatment were formally due on a Monday, coinciding with the timing of the announcement. Yahoo and Fierce Biotech further detailed the findings, characterizing the therapy as an off-the-shelf CAR-T option that shows distinct promise in combating the disease. Background context provided across the coverage focuses on the innovative nature of off-the-shelf CAR-T platforms and their application outside oncology, moving directly into autoimmune conditions like systemic lupus erythematosus. While standard treatments manage symptoms, the introduction of cellular therapies aims for deeper, more durable responses. The transition of prula-cel from its earlier designation as ADI-001 marks a specific developmental milestone that analysts and investors have closely monitored throughout the evaluation phase.


Looking forward, current reporting does not yet specify the exact timeline for subsequent clinical trial phases or regulatory submissions. Observers and market analysts will continue to track how Adicet Bio advances the prula-cel program and whether subsequent patient cohorts corroborate the initial safety and efficacy signals. Readers must consult forthcoming company updates to determine how these early clinical findings translate into broader therapeutic availability.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| The Daily Tribune News | Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis | [Source Link](https://news.google.com/rss/articles/CBMiqwJBVV95cUxPRl9JVXlxOWVRZXJtUm5PM1VMa0t5NDVtdldzMWtDbmpxM3hEbkFrd1hDWFVET0g4N1JpLU5IdENtTjkxUXZhbnd1TXJadmhaWVA0VkFfYVBkdEhVdW40bnZWV3Bjb0U4V0czZjNHODUwc2pBRmZIVFRnU0phclA4QTBJQU9ocmtQUjU0c25FSXBtcVNjanU3anpBNlotNjAtc3JVU252d1RaV25meUE3RTNXTTNMb3k0aml2MWtYeUlKMGw5N2RGTlMwYWFuNDg1MDI0Mk15ZWNONEsycWtyY1p0SWo3cU9NNDFlM1VaX205N0pDa0tJc21kUGtJQ1FBSFdaNDZWMFBPSGx5MUdfWW0yX1VRNy01QTBRQVRneEFRdkFheG4xZXZDVQ?oc=5) |
| Investing.com India | Wedbush raises Adicet Bio stock price target on lupus trial data | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxOQzlVU1dmSkluRTJieDZfVWdjUU9UaGxiT1ZrLVMxTUlNdHBtNHFhZ3NqdlFBSENTTkc0NG9xZmMtVUFXQmJ0amVDa1c3b2cwbmQyTUhnVVVuMFhYbzB5Q19SbkNqUHBLLUJaY0pnUGoyalhIenpiVkRhSWNpVkhnYmpYWkxkOER1UWpFVjA0UkIzZDJJTDVzbmFkLWtuNktRV2ZVNm1qOHJMdEYxeW5UVVN5bGIwR0NUS1hSeVFVY3JuM00?oc=5) |
| Stock Titan | Data on a possible lupus treatment are due Monday | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxNX1RlSjl3ZEFnVGQ2UzVPMlpQNnFFbnVYNXFZUVFnSXJTNW1PWkhkQ3JjUDBnUGJISXBnTkN1eXF3T0tTblgzNlk2SVE2WC1FNTExcGVmZHBPSlh4TXJMdjl2YzJ5TUM4bW04Wk9kVkhGdmh5cjRncTFtVXpxVktTa05LZ2p4bnhwRUtMaWh2SnB4bWJaTGhTWXptaUo0ZzBWdHlxb0ZlSkxLSlRwUm9mN1FYZkNLV1dTS1Nn?oc=5) |
| Yahoo | An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus | [Source Link](https://news.google.com/rss/articles/CBMiigFBVV95cUxNWm1yUmc1bm81dk5uQ3dBdWlTRjJmbFNudmpkWktFcnUzOXdsaVdYZ3pObXV4T2pYcnNDUlpnUkpxWTRGbjY1UHJZY1dMbkd4MHc5SW1jR1dCV0JQSE1oR3lUcmprSVptdDRlRFJhZ2FkRVlWZkpZS1o4N1p0UlZQdGJMNmpYaTdGcFE?oc=5) |
| Fierce Biotech | Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxQV3haMS1taUx5UlA4aXJERVQyTVBlSFhtT0lUeXY3aGRJOTd3a050M3dzX041TTNLTkYwdEw0WUstcFZvQWMtY1V2NzdQbzVIZzNpQ1gzZHpTVmROYTZ5U0JnUy1MM3lBRHM1a3hJQ0U1MTVnX09WUGpxaE84S3NIWW1oS1B4OC1sN0ItMFRhWnQ4WEVpTmNFYXl1TmVjSTlnQTRjTVBwRHVzSm96TE9vd2h4aTNZeVhlVWNJ?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-09-28/adicet-bio-car-t-sparks-lupus-remissions-in-early-trial-as-new-era-of*
